AM Squared Ltd Buys 1,200 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

AM Squared Ltd raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 600.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,400 shares of the biotechnology company’s stock after acquiring an additional 1,200 shares during the period. Sarepta Therapeutics comprises approximately 0.4% of AM Squared Ltd’s portfolio, making the stock its 20th biggest holding. AM Squared Ltd’s holdings in Sarepta Therapeutics were worth $175,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Mizuho Markets Americas LLC grew its position in Sarepta Therapeutics by 22.3% during the third quarter. Mizuho Markets Americas LLC now owns 399,065 shares of the biotechnology company’s stock valued at $49,839,000 after acquiring an additional 72,765 shares during the last quarter. Simplify Asset Management Inc. grew its position in Sarepta Therapeutics by 84.6% during the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after acquiring an additional 88,474 shares during the last quarter. CIBC Asset Management Inc grew its position in Sarepta Therapeutics by 3.3% during the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after acquiring an additional 86 shares during the last quarter. Huntington National Bank grew its position in Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 175 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. grew its position in Sarepta Therapeutics by 3.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after acquiring an additional 145 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 14.99 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SRPT. Evercore ISI cut their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. StockNews.com upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, Piper Sandler cut their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. One research analyst has rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $181.33.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $104.54 on Friday. Sarepta Therapeutics, Inc. has a 1-year low of $78.67 and a 1-year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The business has a fifty day moving average price of $123.72 and a 200-day moving average price of $132.36. The company has a market capitalization of $9.99 billion, a PE ratio of 83.63 and a beta of 0.81.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.